Actively Recruiting
Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma, Non Small Cell Lung Cancer, and Hepatocellular Carcinoma Treated With PD-1/PDL-1 Inhibitors
Led by Daniel Keizman · Updated on 2026-03-20
300
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating the role of Galectin-3 (Gal-3), a protein involved in cell processes and immune regulation, in patients with renal cell carcinoma, transitional cell carcinoma, non small cell lung cancer, and hepatocellular carcinoma treated with PD-1/PDL-1 inhibitors. The study aims to understand how Gal-3 levels relate to treatment response, survival, and side effects, as Gal-3 may affect tumor progression and reduce the effectiveness of immunotherapy. This observational study involves measuring Gal-3 blood levels using an FDA-approved automated system called the Architect platform, ensuring accurate and consistent results. Blood samples are collected before each PD-1/PDL-1 inhibitor treatment and stored for analysis. Clinical and laboratory data, including liver function and adverse events, are also collected throughout the study period. Participants will be monitored over three years with regular blood draws and clinical evaluations before each immunotherapy cycle. Researchers will analyze the correlation between Gal-3 levels and patient outcomes such as treatment response and side effects. The study seeks to improve understanding of how Gal-3 influences immunotherapy results to optimize future treatments for these cancers.
CONDITIONS
Brief Title
Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Must be able to read and understand the informed consent form (ICF) and follow protocol requirements
- Patients aged 18 years or older
- Patients diagnosed with renal cell carcinoma, transitional cell carcinoma, non small cell lung cancer, or hepatocellular carcinoma
- Patients treated with PD-1/PDL-1 inhibitors
- Patients prior to receiving the first cycle of PD-1/PDL-1 inhibitors
- Willingness to participate throughout the study duration
You will not qualify if you...
- Female participants who are pregnant, breastfeeding, or planning pregnancy during the study period
- Male participants whose partners are planning pregnancy during the study period
- Female participants of child-bearing potential who cannot agree to use reliable birth control during the study and for 1 month after the last dose
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 3 years
Blood tests are performed to measure serum Galectin-3 levels, blood count, and liver function.
Duration - 3 years
Participants are monitored over time to analyze Galectin-3 level fluctuations and correlate these with treatment outcomes and side effects during PD-1/PDL-1 inhibitor therapy.
Trial Site Locations
Total: 1 location
1
Tel Aviv Sourasky Medical Center
Tel Aviv, Israel, Israel, 64239
Actively Recruiting
Research Team
D
Daniel Keizman, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here